Operational Update

IXICO plc

("IXICO", the "Company" or the "Group")

IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer's Disease and vascular experts

-Appointments announced at 2025 CTAD Conference form part of a concerted dementia research and product innovation strategy, particularly in the area of vascular biomarkers -

01 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate effect.

The announcement is being made as part of IXICO's participation in the 18th CTAD conference (Clinical Trials on Alzheimer's Disease) which starts today. CTAD is an annual cornerstone event in Alzheimer's Diseases (AD) clinical research, where IXICO will be presenting research on its capabilities for the accurate assessment of positron emission tomography (PET) imaging in clinical trials.

Professor Micheal Weiner, MD.

Michael is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI), which is the largest observational study in the world concerning Alzheimer's Disease. Michael's full biography is available in the notes at the bottom of this announcement.

Professor Joanna Wardlaw, MD, CBE.

Joanna is a is Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Joanna's full biography is available in the notes at the bottom of this announcement.

IXICO Vascular Biomarker Innovation

The appointments support IXICO's strategy to deepen its presence in Alzheimer's Disease and develop a series of biomarker algorithms to identify and measure vascular abnormalities which are a common contributing factor in neurodegenerative disease where MRI can provide an established biomarker for vascular abnormalities. While particularly relevant for screening, safety and efficacy in AD, measuring vascular components and abnormalities has wider applications in other neurological therapeutic areas such as Cerebral Amyloid Angiopathy (CAA), Stroke, and Multiple Sclerosis. The first in a series of planned vascular biomarker algorithms is already being made available to IXICO clients on their clinical trials with further releases planned for the current financial year.

Robin Wolz, Chief Scientific Officer of IXICO, commented: "It is exciting to be working with Professor Weiner and Professor Wardlaw reflecting IXICO's commitment to advancing the understanding of the interplay between Alzheimer's disease and cerebrovascular pathology. Collaborating with distinguished experts in the field directly supports our work to develop and validate vascular biomarker algorithms that address a critical gap in current AD trials.

By enabling more precise screening, a better understanding of the multiple factors and causes involved in disease, and providing sensitive measures of vascular burden throughout the trial, these biomarkers have the potential to significantly improve trial design and the interpretability of efficacy results. These appointments mark an important step in IXICO's strategy to broaden our biomarker innovation portfolio and deepen our engagement in Alzheimer's disease."

Ends

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

About Michael Weiner, MD

Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer's disease and other brain disorders. Recently he has focused on developing voice agents for assessments in AD clinical trials.

Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, a 19-year national longitudinal study of over 3,500 subjects which is aimed at validating biomarkers for Alzheimer's disease at 63 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 100,000 participants.

Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000 peer reviewed research papers and 71 book chapters. He has received numerous honors including the Young Investigator Award of the American College of Cardiology in 1976, and more recently, the Nancy and Ronald Regan Award from the Alzheimer's Association, the Potamkin Prize of the American Academy of Neurology, a Docteur Honoris Causa Degree from Paul Sabatier University, Toulouse, France in 2019, and the Henry Wisniewski Lifetime Achievement Award in Alzheimer's Disease Research, from the Alzheimer's Association in 2021.

About Professor Joanna Wardlaw, CBE, MB ChB (Hons), MD, FRCR, FRCP, FMedSci, FRSE

Joanna is a is Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain and its blood supply, and treatments to improve blood flow to the brain, including thrombolytic drugs that are now in routine use to treat stroke, and more recently treatments for small vessel disease and vascular dementia. Working with many colleagues, she has been instrumental in advancing understanding of the causes of cerebral small vessel disease and is now testing treatments in clinical trials.

She has set up national research imaging facilities, co-ordinated international research networks, advanced stroke care worldwide and published over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences, she has received awards from many UK and international brain and heart organisations and was made a Commander of the Order of the British Empire (CBE) for services to Medicine and Neuroscience in 2016.